Highlights
Candesartan 16 mg significantly reduces the frequency of monthly migraine days in patients with episodic migraine compared to placebo.
The treatment demonstrates a favorable safety profile, with dizziness being the most common adverse event but low rates of discontinuation.
Triple-blind methodology across multiple European centers provides high-quality evidence for the repurposing of this antihypertensive agent in neurology.
Introduction: The Unmet Need in Migraine Prophylaxis
Migraine remains a leading cause of global disability, particularly among adults in their peak productive years. While the therapeutic landscape has expanded recently with the introduction of CGRP-targeted therapies, there remains a critical need for accessible, cost-effective, and well-tolerated oral preventive treatments. Traditional first-line oral preventives, such as beta-blockers, anticonvulsants (topiramate), and tricyclic antidepressants, are often associated with systemic side effects that lead to high discontinuation rates. In this context, the repurposing of angiotensin II receptor blockers (ARBs), specifically candesartan, has gained interest based on preliminary small-scale studies and clinical anecdotes.
Study Design and Methodology
The study was a randomised, triple-blind, placebo-controlled, parallel-group, phase 2 trial conducted across nine hospitals in Norway and one in Estonia. This rigorous design aimed to eliminate bias by masking participants, site personnel, and the trial statistician to the treatment allocation.
Patient Population and Randomization
The trial enrolled 534 adults aged 18-64 who experienced between two and eight migraine attacks per month, characterizing them as having episodic migraine. After exclusions, 457 participants were randomly assigned in a 1:1:1 ratio to receive oral candesartan 16 mg, candesartan 8 mg, or a matching placebo once daily for 12 weeks. The baseline characteristics were well-balanced, with a mean age of 38.7 years and a female predominance (86%), which is consistent with the general migraine population.
Intervention and Endpoints
While participants were permitted to use acute migraine medications during the trial, other preventive treatments were strictly prohibited to ensure the efficacy observed could be attributed to the study drug. The primary endpoint was the change in the mean number of migraine days per four-week period from the baseline to the final month of treatment (weeks 9-12). The analysis followed an intention-to-treat (ITT) principle, ensuring that results reflected real-world clinical use.
Key Findings: Clinical Efficacy of Candesartan
The results of the trial provide compelling evidence for the efficacy of candesartan at a 16 mg dose. At baseline, participants experienced an average of 5.7 migraine days per month. By the end of the treatment period (weeks 9-12), the reduction in migraine days was significantly greater in the candesartan 16 mg group compared to the placebo group.
Primary Endpoint Results
The candesartan 16 mg group saw a reduction of 2.04 days (95% CI 1.65–2.41) compared to a reduction of only 0.82 days (0.38–1.23) in the placebo group. This represents a statistically significant difference of -1.22 days (p < 0.0001). This magnitude of effect is comparable to that seen in many registered first-line preventive medications, marking candesartan as a clinically meaningful option for patients who may not tolerate or have access to newer biologics.
The Role of Dosage
The trial included an 8 mg arm to explore dose-response relationships. While the 16 mg dose showed the most robust statistical significance, the inclusion of the 8 mg arm allows clinicians to consider a titration strategy for patients sensitive to the medication’s hemodynamic effects.
Safety and Tolerability Profile
One of the primary barriers to successful migraine prevention is the side effect profile of the medication. In this trial, candesartan was generally well-tolerated. The most frequently reported adverse event was dizziness, appearing in 30% of the 16 mg group versus 13% in the placebo group. This is a known effect of ARBs due to their primary role in blood pressure regulation.
Importantly, the rate of adverse events leading to discontinuation was low and equal between the 16 mg group and the placebo group (3% each). Serious adverse events were rare, occurring in 3% of the 16 mg group and 1% of the placebo group, further supporting the safety of using candesartan in a non-hypertensive migraine population.
Clinical Interpretation and Expert Commentary
The success of candesartan in this trial reinforces the hypothesis that the renin-angiotensin-aldosterone system (RAAS) plays a role in the pathophysiology of migraine. While the exact mechanism remains a subject of investigation, it is hypothesized that ARBs may modulate neurogenic inflammation, improve cerebrovascular autoregulation, or exert neuroprotective effects via the AT2 receptor by blocking the AT1 receptor.
Comparison with Existing Therapies
Clinicians often face a dilemma when patients fail initial therapies like propranolol or amitriptyline. Candesartan offers a distinct mechanism of action and a side-effect profile that lacks the cognitive dampening often associated with topiramate or the weight gain associated with valproate. Furthermore, its once-daily dosing and generic availability make it a highly practical choice in various healthcare settings.
Limitations and Considerations
Despite the positive results, the study authors and independent experts note that the trial duration was limited to 12 weeks. Migraine is a chronic condition, and long-term efficacy and safety data beyond three months are essential. Additionally, while the triple-blind design is a strength, the study was conducted primarily in Northern Europe, suggesting a need for validation in more diverse ethnic populations to ensure generalizability.
Conclusion
The Phase 2 trial of candesartan for episodic migraine prevention provides high-quality evidence that a daily dose of 16 mg is both effective and safe. By achieving a significant reduction in migraine days with a tolerability profile comparable to placebo in terms of discontinuation, candesartan stands out as a viable, evidence-based alternative to traditional preventives. Clinicians should consider candesartan as a valuable tool in the individualized management of migraine, particularly for patients seeking oral options with minimal systemic side effects.
Funding and Trial Registration
This study was funded by the Norwegian Research Council. The trial is registered with ClinicalTrials.gov, number NCT04574713.
References
Øie LR, et al. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2025 Oct;24(10):817-827. doi: 10.1016/S1474-4422(25)00269-8. PMID: 40975098.
